公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2018 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study | Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG ; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Havel L; Pauk N; Singh J; Murakami S; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators | The Lancet Oncology | 468 | 397 | |
2009 | First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009 | Soo R.A; Anderson B.O; Cho B.C; CHIH-HSIN YANG ; Liao M; Lim W.-T; Goldstraw P; Mok T.S. | The Lancet Oncology | 23 | 20 | |
2011 | INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer | Wu Y.-L; Park K; Soo R.A; Sun Y; Tyroller K; Wages D; Ely G; CHIH-HSIN YANG ; Mok T. | BMC Cancer | 79 | 61 | |
2019 | Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos | Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N; Kim D.-W; Tan D.S.W; CHIH-HSIN YANG ; Azrif M; Mitsudomi T; Park K; Soo R.A; Chang J.W.C; Alip A; Peters S; Douillard J.-Y. | Annals of Oncology | 209 | 174 | |
2017 | Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer) | Nokihara H; Lu S; Mok T.S.K; Nakagawa K; Yamamoto N; Shi Y.K; Zhang L; Soo R.A; CHIH-HSIN YANG ; Sugawara S; Nishio M; Takahashi T; Goto K; Chang J; Maemondo M; Ichinose Y; Cheng Y; Lim W.T; Morita S; Tamura T. | Annals of Oncology | 74 | 68 | |
2010 | The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer | Cho B.C; Kim J.H; Soo R.A; CHIH-HSIN YANG | Yonsei Medical Journal | 5 | 4 | |
2017 | Scientific Advances in Thoracic Oncology 2016 | Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG ; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R. | Journal of Thoracic Oncology | 42 | 31 | |
2019 | Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study | Hochmair M.J; Morabito A; Hao D; Yang C.-T; Soo R.A; CHIH-HSIN YANG ; Gucalp R; Halmos B; Wang L; Märten A; Cufer T. | Future Oncology | 71 | 67 | |
2018 | Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study | Hochmair M.J; Morabito A; Hao D; Yang C.-T; Soo R.A; CHIH-HSIN YANG ; Gucalp R; Halmos B; Wang L; Golembesky A; Märten A; Cufer T. | Future Oncology | 88 | 87 | |
2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer | Yun M.R; Choi H.M; Lee Y.W; Joo H.S; Park C.W; Choi J.W; Kim D.H; Kang H.N; Pyo K.-H; Shin E.J; Shim H.S; Soo R.A; CHIH-HSIN YANG ; Lee S.S; Chang H; Kim M.H; Hong M.H; Kim H.R; Cho B.C. | EMBO Molecular Medicine | 38 | 34 |